Methotrexát Denk

Methotrexate, the active ingredient in Methotrexát Denk, is an antimetabolite (folate antagonist) presented as a subcutaneous injection solution for subcutaneous use. It treats rheumatoid arthritis, psoriasis, certain leukemias and other serious conditions in appropriate patients.

GNH USA supplies Methotrexát Denk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Methotrexate is used across several autoimmune and oncologic disease pathways.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin plaque formation and severity. - Acute lymphoblastic leukemia: interferes with malignant cell proliferation. - Osteosarcoma: inhibits tumor growth. - Ectopic pregnancy: terminates trophoblastic tissue.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting. - Fatigue or weakness. - Oral mucosal ulceration. - Mild to moderate liver enzyme elevation. - Transient rash or itching. - Decreased white blood cell count.

Serious or Rare Side Effects: - Severe hepatotoxicity or liver failure. - Pulmonary fibrosis or interstitial pneumonitis. - Life‑threatening infections due to immunosuppression. - Aplastic anemia or bone‑marrow failure. - Acute renal impairment. - Anaphylactic or severe hypersensitivity reactions.

Methotrexát Denk requires careful monitoring and specific safety measures.

- Pregnancy: contraindicated (Category X); avoid use in pregnant patients. - Liver function: perform baseline and periodic liver enzyme tests. - Renal function: assess creatinine clearance before initiation and during therapy. - Hematology: obtain regular complete blood counts to detect cytopenias. - Concomitant folate: consider folic acid supplementation to reduce toxicity. - Immunosuppression: monitor for signs of infection and advise patients to seek prompt medical attention. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexát Denk can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Aminoglycoside antibiotics: heightened risk of nephrotoxicity. - Live vaccines: risk of uncontrolled infection. - High‑dose vitamin C: may reduce methotrexate efficacy. - Trimethoprim‑sulfamethoxazole: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Proton pump inhibitors: may affect methotrexate absorption. - Azathioprine: additive immunosuppressive effect. - Phenytoin: may increase methotrexate clearance, reducing efficacy. - Alcohol: potentiates hepatic toxicity. - Sulfonamides: possible additive toxicity on blood cells.